News Overview

Of Rs 3.75 per share

Overseas debt will get entirely paid in the coming quarters, the company said.

L&T Technology Services released its first Sustainability Report for the year 2020-21, with a roadmap to achieve carbon and water neutrality by 2030. LTTS Sustainability Report covers its various ESG initiatives which are built on the pillars of transparency, accountability, responsibility, compliance and trust, to drive an ethically progressive and reliable business model, robust enough to meet emerging challenges. The report, conforming to the Global […]

Business Wire IndiaSouth Asia’s largest & Asia’s leading higher EdTech major – upGrad, today reported turning a profit spurred by a 150% growth Y-o-Y in revenues and a stable 70% gross margin, across all its income streams.    upGrad is now well-positioned as the most integrated Higher Edtech company in the world – spanning all aspects of LifeLongLearning from undergrad courses, test prep, on-campus learning, […]

Hindalco Industries Ltd has added 12.39% over last one month compared to 9.56% gain in S&P BSE Metal index and 0.04% drop in the SENSEX

Zydus Lifesciences (formerly known as Cadila Healthcare) received Prior Approval Supplement (PAS) approval from the USFDA to market Mycophenolate Mofetil for Injection USP, 500 mg/vial (US RLD: CellCept injection).

The companys board on Friday (18 March) declared an interim dividend of Rs 3.75 per share.

The domestic equity barometers traded with modest losses in early trade. The Nifty as trading below the 17,300 mark. Metals, IT and healthcare stocks advanced while FMCG, banks and financials shares declined. At 09:21 IST, the barometer index, the S&P BSE Sensex, was down 72.01 points or 0.12% to 57,791.92. The Nifty 50 index lost 14.25 points or 0.08% to 17,272.80. Hindalco (up 3.69%), Maruti […]

RRVL acquires 89% equity stake in Purple Panda Fashions, which owns and operates the Clovia business Founding team to continue to drive the business in the next phase of growth.

Glenmark Pharmaceuticals on Monday announced that it has received final approval by the United States Food & Drug Administration (USFDA) for its lacosamide tablets.